alexa Metformin: Friend Or Foe Of The Polycystic Ovary?
ISSN: 2161-1017

Endocrinology & Metabolic Syndrome
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd World Congress on Polycystic Ovarian Syndrome
October 05-07, 2016 Orlando, Florida, USA

Suman Rice
St. George’s, University of London, UK
Posters & Accepted Abstracts: Endocrinol Metab Syndr
DOI: 10.4172/2161-1017.C1.015
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders in women. It is diagnosed by hyperandrogenemia, menstrual disturbances i.e., oligo- or anovulation, and/or polycystic ovaries on ultrasound (Rotterdam criteria). It is associated with insulin resistance, hyperinsulinemia and obesity. In the USA, the medical cost of its diagnosis and treatment during 2005 was around $4 billion, with a similar prevalence in the UK. With increasing rates of obesity, the number of women diagnosed with PCOS is likely to rise. The defining abnormality and the morphological feature of the polycystic ovary is the increase in the number of follicles compared with normal ovaries. The follicles in these ovaries over-produce androgens, leading to hyperandrogenemia. The high insulin levels present in a substantial number of women with insulin-resistant PCOS further exacerbate the over-production of androgens. Metformin, an insulin sensitizer, is widely prescribed in PCOS is primarily aimed at improving insulin sensitivity. It is well established however, that metformin can decrease hyperandrogenemia, improve menstrual cycles and ovulation rates without major changes of systemic insulin sensitivity. Could metformin act directly on the ovary? This talk will outline numerous lines of evidence from in vitro studies on human ovarian cells, showing that metformin directly alters ovarian steroidogenesis- in terms of androgen and oestrogen output. It can also alter insulin signaling in these cells affecting glucose uptake and hence potentially follicle growth. We will discuss whether this can be translated to an evidence-based approach to metformin’s use in treating women with PCOS.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version